Combination Chemotherapy with Cis-platinum, Adriamycin, Mitomycin-C (PAM) in Patients with Advanced Bladder Cancer
| Autor: | H Hatzichristou, P A Kosmidis, C Bacoyiannis |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Male
Oncology medicine.medical_specialty Nausea Mitomycin medicine.medical_treatment Gastroenterology Mitomycins 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Pharmacology (medical) Doxorubicin Prospective Studies 030212 general & internal medicine Prospective cohort study Aged Pharmacology Cisplatin Chemotherapy business.industry Remission Induction Mitomycin C Combination chemotherapy Middle Aged Infectious Diseases Urinary Bladder Neoplasms 030220 oncology & carcinogenesis Vomiting Female medicine.symptom business medicine.drug |
| Zdroj: | Journal of Chemotherapy. 2:397-400 |
| ISSN: | 1973-9478 1120-009X |
| DOI: | 10.1080/1120009x.1990.11739052 |
| Popis: | Thirty patients with advanced bladder cancer received combination chemotherapy with cis-platinum, adriamycin and mitomycin C. Two patients (6.6%) responded completely and survived 24 and 30 months. Partial response was noted in 14 patients (46.6%) who had a median survival of 9.6 months. Eight patients (26.6%) had stable disease with a median survival of 5 months whereas in 6 patients (20%) their disease progressed with a median survival of 3 months. The amelioration of hematuria, regardless of response, was impressive. Nausea and vomiting were the commonest side effects. Myelotoxicity was mild and reversible. We conclude that PAM chemotherapy is effective and well tolerated in patients with advanced bladder cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|